A Case of Variegate Porphyria in Association With Coeliac Disease and Bisphosphonate Associated Dental Osteonecrosis by Ogundipe, Olayinka A.
Case Report J Clin Med Res  •  2009;1(5):292-296       
Press Elmer 
Articles © The authors, Journal compilation © J Clin Med Res and Elmer Press™, www.jocmr.org
A Case of Variegate Porphyria in Association With 
Coeliac Disease and Bisphosphonate Associated 
Dental Osteonecrosis
Olayinka A. Ogundipe
Abstract
This case describes an older patient with a rare diagnosis of varie-
gate porphyria presenting with acute abdominal pains and bloating, 
intermittent loose stools and jaw pains following surgical repair of 
an osteoporotic hip fracture. She was noted to have acute hypona-
traemia. All the abdominal symptoms and the hyponatraemia were 
initially attributed to an acute episode of variegate porphyria with 
an accompanying syndrome of inappropriate antidiuretic hormone 
secretion. However, following further evaluations necessitated by 
the incomplete resolution of the abdominal symptoms, it became 
apparent that some of the persisting symptoms were due to a con-
current and new presentation of serology positive coeliac disease. 
The jaw pains were established to be due to dental osteonecrosis in 
association with the use of bisphosphonate therapy for treatment of 
osteoporosis. The various symptoms and signs subsequently settled 
uneventfully following institution of appropriate management op-
tions for the various coexisting diagnoses.
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Case Report
A 73 years old caucasian woman of Scottish descent was 
admitted to hospital following a fall that resulted in a left 
femoral neck fracture. Her medical history was notable for 
variegate porphyria, hypothyroidism, chronic atrial fibrilla-
tion, rheumatoid arthritis and renal tubular acidosis. Medi-
cations on admission included paracetamol, omeprazole, le-
vothyroxine, digoxin, warfarin and oral sodium bicarbonate 
supplements. 
She had been previously diagnosed with variegate por-
phyria in her forties based on clinical features and labora-
tory tests. The diagnosis followed relevant urinary and faecal 
samplings during a presentation to hospital with acute ab-
dominal symptoms and vesicular cutaneous eruptions to the 
sun-exposed areas of both upper extremities. There was also 
increased facial pigmentation. She had remained relatively 
symptom free since then, and had adhered conscientiously 
to the general counselling advice given (e.g. avoidance of 
precipitants of acute porphyria crises like multiple itemised 
medications, avoidance of low calorie diets, and avoidance 
of excessive exposure to sunlight). 
Surgical repair of the hip fracture was performed with 
a dynamic hip screw (DHS). The immediate postoperative 
period was unremarkable. However, she subsequently devel-
oped a complication with low grade chronic infection to the 
DHS site. This required a period of antibiotics and the DHS 
thereafter required surgical revision to a gamma nail. Fol-
lowing the orthopaedic interventions she continued with a 
period of multidisciplinary rehabilitation. Multidisciplinary 
falls risk and osteoporosis assessments were completed and 
oral calcium/vitamin D supplements with weekly oral alen-
dronic acid were prescribed. 
Some six weeks post-operatively she developed acute 
abdominal pains. This was associated with abdominal bloat-
ing and intermittent loose stools of a non-infective nature. 
She also reported the onset of pains in the right maxillary 
region. 
An acute-onset hyponatraemia developed and progres-
sively worsened to a nadir of serum sodium concentration 
116 mmol/L (normal 135 – 145). The evolving symptoms 
included anorexia, lethargy and gait imbalance. Mild periph-
eral oedema was noted. Paired serum and urine osmolalities 
were 245 mOsm/Kg (normal 280 - 296) and 301 mOsm/Kg 
respectively. Urinary sodium level was high at 89 mmol/L. 
She had normal serum cortisol responses on short synacthen 
testing. Other relevant evaluations including serum potassi-
um, calcium, magnesium, triglycerides, serum protein elec-
trophoresis, urine Bence-Jones protein screening, and chest 
X-ray were unremarkable. She had a mild dimorphic anae-
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mia due to a combination of iron and folic acid deficiencies. 
Serum vitamin B12 level was normal. Serum digoxin levels 
were within the normal range and thyroid function tests sug-
gested optimal supplementation. Serum renal function tests 
were unremarkable with an estimated glomerular filtration 
rate (eGFR) of over 60 ml/hr.
A general surgical review supported by abdominal com-
puterised tomography scanning did not identify any acute 
surgical cause for the abdominal pains. A dental review es-
tablished that the jaw pains were due to dental osteonecro-
sis involving the right maxillary bone. The symptoms of the 
osteonecrosis gradually responded to conservative manage-
ment involving discontinuation of the alendronic acid, oral 
and dental hygiene measures, oral antibiotics for secondary 
infection,  and  analgesia. A  medical  review  attributed  the 
acute abdominal symptoms and acute onset hyponatraemia 
to an acute episode of variegate porphyria. 
She showed some symptomatic improvement with the 
institution of a cautious regimen of fluid restriction as initial 
management for possible SIADH-associated hyponatraemia; 
and a high calorie diet as initial management for the sus-
pected acute porphyria episode. The nutritional management 
was supervised by a dietician. A period of supplemental na-
sogastric (NG) tube feeding was required, aimed at provid-
ing a high calorie carbohydrate intake, and whilst striving 
to maintain an initial restricted fluid intake target of 1 litre 
in 24 hours.  On this management regimen, the serum so-
dium concentration normalised to 138 mmol/L, the abdomi-
nal pains resolved and there was marked improvement in the 
lethargy and gait imbalance. The supplemental NG feeding 
was discontinued when her appetite improved to the point 
of allowing satisfactory oral food intake. The fluid restric-
tion was progressively relaxed to 1.5 litres in 24 hours, and 
subsequently to 2 litres in 24 hours without recurrence of the 
hyponatraemia.
Despite  the  initial  clinical  and  biochemical  improve-
ments described above, she reported persistence of intermit-
tent abdominal bloating and recurring bouts of loose stools. 
Multiple stool samples for routine microscopy, cultures and 
clostridium difficile toxin screens returned clear. These per-
sistent features, along with the presence of the dimorphic 
anaemia, informed the subsequent decision to screen her for 
coeliac disease. 
Her  IgA  tissue  transglutaminase  antibody  (tTG-IgA) 
levels returned markedly elevated at 125 AU (normal 0.1 - 
7.9 AU). She received appropriate counselling towards un-
dertaking an upper gastrointestinal endoscopy (UGIE), to 
allow  for  the  (gold-standard)  histological  confirmation  of 
the diagnosis of coeliac disease from distal duodenal biop-
sies. However, she declined an UGIE citing physical frailty 
and all the recently endured medical hardships. Following 
further counselling she consented to an empirical trial of a 
gluten-free diet (GFD) on the clinical suspicion of possible 
serology positive coeliac disease. 
The GFD was cautiously introduced under the close su-
pervision of a dietician so as to avoid a sudden reduction to 
her calorie requirements and the risk of precipitating another 
episode of acute porphyria. Following establishment on the 
GFD diet for about three weeks and discontinuation of all 
fluid restrictions, the residual abdominal symptoms of bloat-
ing and loose stools resolved. The serum sodium and other 
relevant serum biochemistry remained normal. Of note how-
ever was a marked urinary sodium loss that persisted on a 
pre-discharge sample (urinary sodium 159 mmol/L). 
She thereafter progressed well with a further period of 
multidisciplinary rehabilitation, regaining functional inde-
pendence with her transfer abilities and with mobility sup-
ported with the use of a wheeled zimmer frame as a physical 
aid. Modified cutlery assisted her in overcoming the restric-
tions of rheumatoid arthritis to both hands. Minor assistance 
was required with washing and dressing, and she was dis-
charged home with her family providing informal assistance 
with care. 
Following  discharge  from  hospital  she  has  remained 
symptomatically well on the GFD, with repeat levels of her 
tTG-IGA levels showing reducing titres to 70.7 AU (four 
months following commencement of a GFD).
Discussion
  
Porphyria
The porphyrias are a rare group of medical conditions char-
acterised by abnormalities in the haem biosynthetic pathway 
[1]. Most cases are inherited (e.g. acute intermittent por-
phyria, hereditary coproporphyria and variegate porphyria), 
whereas some cases may be an acquired disorder (e.g. por-
phyria cutanea tarda). The porphyrias can be classified fur-
ther according to the predominant source of overproduction 
of porphyrias and precursors of porphyrin (e.g. hepatic or 
bone marrow), or based on the predominant clinical presen-
tation (neurovisceral or cutaneous) [1-6]. 
Variegate or ‘mixed’ porphyria (VP) is considered to be 
a hereditary disorder which is characterised by a reduction in 
the hepatic protoporphyrinogen oxidase enzyme of the haem 
synthetic pathway (at the stage of oxidative conversion of 
protoporphyrinogen IX to form protoporphyrin IX). VP can 
remain asymptomatic for long periods, but during an acute 
episode individuals may present with neurovisceral and/or 
cutaneous symptoms or signs, some of which may be serious 
or even life-critical [1].  
Cases of VP are described rarely in the medical litera-
ture. Often, these cases describe the practical difficulties of 
establishing a firm diagnosis, and the various added prob-
lems in managing cases when they present with acute ex-
acerbations [1-10]. Hyponatraemia and abdominal pains are 
well recognised manifestations of the acute porphyrias and 
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can occur irrespective of the subtype. Nevertheless, consid-
eration of the porphyrias as a possible diagnosis in routine 
practise can still be easily overlooked because of the rarity, 
and because hyponatraemia and abdominal pains are fairly 
common presentations that can occur in commoner differen-
tial diagnoses. 
For first presentations in patients without a known or 
pre-existing diagnosis of porphyria, it has been suggested 
that  the  pragmatic  emphasis  of  the  acute  period  of  care 
should be a focus on establishing the diagnosis of an acute 
porphyria, and the early institution of standard therapeutic 
options. As the acute treatment strategies generally overlap, 
it may be prudent to concentrate the focus of initial manage-
ment on the generic treatments that may reduce morbidity 
and mortality, and not to defer treatment on the basis of on-
going efforts to accurately subtype the porphyria, a diagnos-
tic process that often continues into the post-acute phase and 
that is usually informed by evolving clinical and laboratory 
evaluations [1]. 
In the index case, it is hypothesised that stressful triggers 
(independently or in combination) such as the preceding ma-
jor surgeries, anaesthesia, infection, reduced calorie intake in 
the post-operative phase, medications, and/or pain may have 
variably contributed to the precipitation of an acute onset of 
porphyria symptoms/signs in an individual with known VP, 
but with a preceding prolonged symptom free phase of about 
thirty years. 
The mechanism of the hyponatraemia seen in acute por-
phyria is not certain but postulates include a link to the syn-
drome of inappropriate antidiuretic hormone secretion (SI-
ADH), and a resultant renal tubular retention of free water. 
This patient had serum and urine osmolalities, and elevated 
urine sodium levels that would be supportive of SIADH. 
However, according to strict diagnostic specifications, one 
could not state categorically that the hyponatraemia in this 
case was due to SIADH because of the diagnostic restric-
tions/exclusions that could apply e.g. a requirement for eu-
volaemia, normal thyroid function, and normal renal func-
tion amongst others, as well as the fact that the patient was 
taking oral sodium bicarbonate tablets for previously diag-
nosed renal tubular acidosis. 
The use of oral demeclocycline as a therapeutic option 
to manage the acute, severe and symptomatic hyponatrae-
mia was considered in this case. Unfortunately, use of this 
medication is specifically contraindicated in porphyria. The 
option of using intravenous (IV) haematin was also consid-
ered. However, in view of the fairly good initial response 
noted to the fluid restriction and dietary (calorie) modifica-
tions, the option of IV haematin was reserved as a second 
line intervention. A decision was made to use IV haematin if 
she showed signs of clinical deterioration, but as her clinical 
and biochemical picture showed continuous improvement 
she did not require this. 
As some cases of VP may be inherited as an autosomal 
dominant trait, the patient’s grownup children were referred 
to a tertiary clinical genetics department for consideration of 
elective genetic screening, subject to the granting of consent 
after appropriate counselling. Genetic screening is currently 
possible to detect the presence of a splice site mutation in the 
gene for protoporphyrinogen oxidase; a finding that would 
be consistent with a diagnosis of VP [1]. 
Coeliac disease 
Coeliac disease (CD) is an autoimmune condition that is 
probably under-recognised and under-diagnosed [11]. UK 
based studies have described a prevalence rate ranging be-
tween 0.9 - 1.8% [11].  It is now acknowledged that CD has 
the potential to present variably in children, adults or older 
individuals [11-13]. 
The  gastrointestinal  features  of  CD  generally  have 
greater recognition (e.g. chronic or intermittent diarrhoea; 
persistent or recurring and unexplained nausea and vomit-
ing; recurrent abdominal cramps, pain or distension/bloat-
ing; weight loss; and unexplained iron deficiency anaemia or 
dimorphic anaemia) [11]. 
However,  the  non-gastrointestinal  associations  of  CD 
are also being increasingly described and recognised (e.g. 
osteoporosis, osteomalacia, an increased risk of intestinal 
lymphoma,  epilepsy/seizures,  etc),  as  are  its  associations 
with other autoimmune diseases (type 1 diabetes, autoim-
mune thyroid disease, Addison’s disease, etc) [11-14]. 
Individuals with IgA deficiency may return false-nega-
tive IgA-based serological tests (e.g. tissue transglutaminase 
and endomysial antibodies). In these cases, IgG-based sero-
logical tests may be required as part of the diagnostic evalu-
ations. Although not applicable to this patient, false positive 
tissue transglutaminase antibody results have been described 
in individuals with chronic liver disease, myeloma, mono-
clonal gammopathy, and type 1 diabetes [11].  
Regardless  of  a  positive  IgA-tTG  serology  which  is 
suggestive of possible CD, as is the case in this report, it is 
important to emphasise that current guidelines recommend 
histological diagnosis on small intestinal biopsy as being 
essential before a definitive diagnosis of CD can be made, 
and before a GFD would generally be instituted [11, 15]. 
However, as mentioned earlier the patient in this case had a 
strongly positive serology screen but declined the option of 
UGIE after counselling. She however granted consent to a 
trial of a GFD on the clinical suspicion of serology positive 
CD. As the GFD has translated to symptomatic benefit she 
has elected to continue on this. 
Bisphosphonate associated dental osteonecrosis
Bisphosphonates are a recognised and evidence-based man-
agement option for osteoporosis and generally feature high 
up in treatment algorithms. Bisphosphonate associated os-
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teonecrosis  has  previously  been  described  as  a  relatively 
uncommon condition when its incidence is compared to its 
general use in clinical practise. However, the increasing use 
of bisphosphonates variably for the management of osteopo-
rosis, hypercalcaemia, bones pains due to metastatic disease 
or Paget’s disease etc, may with time translate into an in-
creasing incidence of reports of osteonecrosis. It is notewor-
thy that although not isolated to such cases, the trend in the 
reporting of cases has leaned more towards bones around the 
jaw/mouth, those in which high dose bisphosphonates have 
been employed, those on prolonged therapy (in many cases 
greater than one year), and particularly when therapy has in-
volved administration through the intravenous route [16-18]. 
The patient in this report was receiving oral alendronic 
acid (a bisphosphonate) as part of an individualised man-
agement plan for osteoporosis and had been on treatment 
for only a few months. On discontinuation of the alendronic 
acid because of the known association with osteonecrosis, 
the possibility of prescribing alternatives for the osteopo-
rosis was explored e.g. oral strontium ranelate etc. Unfor-
tunately, experience and formulary information on the use 
of strontium ranelate or other alternative osteoporosis treat-
ments in porphyria is limited. This appears to be largely as a 
result of the rarity of the porphyrias.  
Theoretical arguments would suggest that as strontium 
ranelate is not metabolised by and does not inhibit the hepat-
ic cytochrome P450 enzyme, there should be no problems 
if administered to individuals with VP, the latter itself being 
an example of a hepatic porphyria. However, in this case the 
patient declined the option of taking strontium ranelate giv-
en the lack of clinical experience with its use in porphyria.  
Further thoughts and conclusion 
A search of the medical literature produced a solitary report 
of a case of variegate porphyria in an individual with coeliac 
disease. The patient also had beta-thalassaemia minor [7]. 
The current case represents another rare report of variegate 
porphyria in an individual with serology positive coeliac dis-
ease. 
The  medical  literature  identifies  CD  as  a  risk  factor 
for  osteoporosis  with  an  accompanying  association  with 
increased fracture risk [19, 20].  Other risk factors for os-
teoporosis in this case include a postmenopausal status and 
chronic rheumatoid arthritis. This patient developed dental 
osteonecrosis in association with use of an oral bisphos-
phonate that was prescribed for the treatment of osteoporo-
sis. Though by no means proven, it is plausible that dental 
enamel deficiencies may have played a further predisposing 
role in this case, considering that the medical literature also 
proposes that CD may be associated with dental enamel de-
fects [11, 12].
Abdominal complaints are common, and in some in-
stances may be subsequently identified as being due to initial 
presentations of CD, or less commonly due to acute porphyr-
ia. This report serves as a reminder for clinicians to maintain 
a degree of diagnostic openness when symptoms/signs that 
initially appear ‘clear-cut’ do not appear to improve or re-
solve satisfactorily upon institution of initial treatment op-
tions for a primary working diagnosis. This is especially im-
portant when the primary diagnosis is in itself rare. 
In medicine, the term ‘sequence’ is sometimes used in 
reference to a series of consequences arising in an ordered 
manner from a single cause. In this case, it is possible that 
coeliac disease could have predisposed to osteoporosis, and 
the bisphosphonate that was duly prescribed for osteoporosis 
predisposed to dental osteonecrosis. The index case is the 
first describing an individual with variegate porphyria, pos-
sible coeliac disease and bisphosphonate associated osteo-
necrosis. 
Other notable associations in this case include the pres-
ence of the possible SIADH, renal tubular acidosis (type 2 / 
proximal tubular), hypothyroidism and rheumatoid arthritis. 
Renal tubular acidosis is itself associated with osteomalacia 
and proximal myopathy; with muscle weakness being recog-
nised as a risk factor for increased risks of falls.  A predis-
position to falls increases the risk of fractures, particularly in 
individuals with co-existent osteoporosis. 
The presence of many of these varied conditions (varie-
gate porphyria, coeliac disease, hypothyroidism, renal tubu-
lar acidosis and rheumatoid arthritis) in a single individual 
raises a question regarding the possibility of genetic associa-
tions or influences intertwining some or all of them. This is 
an area that future research may want to explore and offer 
confirmatory or refuting evidence.  
Key points
(1) Variegate porphyria is a rare condition and an acute ex-
acerbation can present with abdominal pains and acute hy-
ponatraemia. 
(2)  Management  options  for  acute  porphyria  include 
avoidance of precipitating medications or stressors, provi-
sion of high calorie diets or intravenous glucose supplemen-
tation, and intravenous haematin. 
(3) A rare association between porphyria and coeliac dis-
ease may mask or confuse the clinical picture in individuals 
presenting with abdominal symptoms. 
(4) Coeliac disease can present newly even in older pa-
tients with iron deficiency anaemia, weight loss, or with ab-
dominal symptoms like bloating, cramps and loose bowel 
motions. 
(5) Management options for coeliac disease include a 
gluten  free  diet  under  supervision  and  usually  supported 
with histological monitoring of response. 
(6) The place of serological monitoring of response in 
coeliac disease has not been clearly established, particularly 
in patients that decline, or are unable to undergo upper gas-
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trointestinal endoscopies on an initial diagnosis or response 
monitoring basis. 
(7) Coeliac disease is a risk factor for osteoporosis and 
dental enamel defects.
(8) Bisphosphonates prescribed for the management of 
osteoporosis can predispose to osteonecrosis, with the jaw 
bone regions appearing especially susceptible.  
(9) Genetic screening following counselling for families 
is now a valuable option in the diagnostic armoury for further 
evaluation of suspected index cases or in the blood relatives 
of individuals with porphyrias. Genetic testing has the added 
advantage that tests can be performed even in asymptomatic 
blood relatives; a scenario in which standard urine and faecal 
samplings may prove significantly less rewarding. 
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